Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a late-stage, clinical biopharmaceutical company centered on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The GOSS news feed on Stock Titan brings together company announcements, scientific updates, financial disclosures, and corporate developments that shape the investment and clinical narrative around its pulmonary hypertension programs.
News items for Gossamer Bio frequently cover progress in its registrational Phase 3 trials, including the PROSERA Study in PAH and the SERANATA Study in PH‑ILD. Investors and observers can follow updates on enrollment milestones, planned timelines for topline data, and key clinical endpoints such as six‑minute walk distance (6MWD), time to clinical worsening, and lung function measures. Scientific conference coverage, such as presentations at the European Respiratory Society (ERS) Congress, provides additional context on seralutinib’s mechanistic and translational data.
The GOSS news stream also reflects Gossamer Bio’s broader corporate and pipeline activities. This includes quarterly financial results and business updates, collaboration news with the Chiesi Group, stockholder meeting outcomes, and announcements related to its option agreement to acquire Respira Therapeutics and the investigational inhaled vardenafil candidate RT234. Regular disclosures of employment inducement stock option grants highlight hiring and equity compensation practices under Nasdaq Listing Rule 5635(c)(4).
By monitoring Gossamer Bio news on Stock Titan, readers can track how clinical data, regulatory milestones, scientific presentations, financial performance, and strategic transactions interact within the company’s focused pulmonary hypertension strategy. This page is intended as a central hub for GOSS-related headlines and press releases, helping users follow the evolution of its late-stage programs over time.
Gossamer Bio announced the completion of patient enrollment in the Phase 2 TORREY Study for Seralutinib (GB002), targeting pulmonary arterial hypertension. Topline results are expected in Q4 2022. As of March 31, 2022, Gossamer reported cash, cash equivalents, and marketable securities of $272 million, extending its capital runway into H1 2024. R&D expenses rose slightly to $42.3 million, and net loss was $57.8 million, or $0.76 per share, compared to a loss of $57.6 million, or $0.78 per share, in the year prior.
Gossamer Bio announced the termination of its Phase 2 SHIFT-UC Study of GB004 for ulcerative colitis, as neither treatment arm met primary or secondary endpoints at week 12. The study enrolled 236 participants but showed no meaningful clinical benefit. However, Gossamer is advancing its Phase 2 TORREY Study of seralutinib in pulmonary arterial hypertension, with topline results expected in Q4 2022. As of March 31, 2022, Gossamer reported approximately $272 million in cash, cash equivalents, and marketable securities.
Gossamer Bio reported a net loss of $234 million for the full year 2021, or $3.13 per share, an improvement over 2020's loss. Cash and equivalents totaled $325 million, sufficient to fund operations into late 2023. Two Phase 2 trials, GB004 for ulcerative colitis and Seralutinib for pulmonary arterial hypertension, are ongoing, with results expected in 2022. R&D expenses rose to $170.3 million for 2021, driven by clinical trials. The company plans a conference call for March 3 to discuss its financial results and updates.
Gossamer Bio, Inc. (GOSS) will announce its fourth quarter and full-year 2021 financial results on March 3, 2022. A live conference call and webcast will follow at 4:30 p.m. ET that same day, where management will discuss the financial results and provide a corporate update. Investors can access the live webcast at this link, with a replay available for 30 days on the company’s website. Gossamer Bio focuses on developing therapeutics for immunology, inflammation, and oncology.
Onxeo S.A. has appointed Bryan Giraudo, COO & CFO of Gossamer Bio, as an independent member of its Board of Directors, replacing Thomas Hofstaetter. Giraudo brings extensive financial expertise and a strong network in the U.S. life sciences sector. His appointment aims to strengthen Onxeo's international focus, especially in developing its innovative oncology drug, AsiDNA™, which targets DNA Damage Response (DDR). Chairwoman Shefali Agarwal and CEO Judith Greciet lauded his financial acumen and strategic insights.
Gossamer Bio reported its third quarter 2021 results, highlighting significant cash reserves of $366 million as of September 30, 2021. The company is advancing its clinical programs including Seralutinib, with phase 2 topline results now expected in H2 2022 due to COVID-19 delays. Additionally, the SHIFT-UC study has completed enrollment, with initial results anticipated in Q2 2022. R&D expenses rose to $43.2 million, while the net loss for the quarter was $60.2 million, maintaining the same per-share loss as in 2020.
Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, will report its third quarter 2021 financial results on November 8, 2021. The management team will hold a live conference call at 4:15 p.m. ET to discuss financial results and provide a corporate update. Interested parties can join via domestic and international dial-in numbers or through a live webcast. A replay will be available for 30 days on Gossamer's website, ensuring accessibility for investors and stakeholders.
Gossamer Bio (NASDAQ: GOSS) announced two new CNS-penetrant Bruton’s tyrosine kinase (BTK) inhibitors, GB5121 and GB7208, aimed at treating central nervous system malignancies and diseases. The first-in-human trial for GB5121 is set for Q4 2021, targeting relapsed/refractory primary CNS lymphoma. GB7208 is progressing towards clinical trials with promising preclinical outcomes. Both candidates exhibit superior CNS penetration and selectivity compared to existing treatments, addressing unmet needs in oncology and neurology.
Gossamer Bio, Inc. (NASDAQ: GOSS) has scheduled a conference call and webcast for investors on October 11, 2021 at 2:30 pm ET. The event will focus on the company's new clinical product candidates in immunology, inflammation, and oncology. Management will provide insights into their pipeline and will be available for questions.
Investors can access the live webcast on Gossamer's website or dial in using the provided numbers. A replay will be available for 30 days.
Gossamer Bio, Inc. (NASDAQ: GOSS) has appointed Bryan Giraudo as Chief Operating Officer, maintaining his role as Chief Financial Officer. He joined Gossamer in May 2018 and has significantly contributed to the company's financial and organizational strength. Giraudo's promotion reflects his expanding leadership role. Before joining Gossamer, he was a Senior Managing Director at SVB Leerink and a Managing Director at Merrill Lynch's Global Healthcare Investment Banking Group. Gossamer Bio focuses on therapeutics in immunology, inflammation, and oncology.